Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, randomized, controlled study, aiming to evaluate the efficacy and safety of CAN008 administered once-weekly with rRT for treating first tumor recurrence in patients with GBM.


Clinical Trial Description

This is a multi-center, randomized, controlled clinical trial to evaluate the efficacy and safety of CAN008 administered once-weekly with re-radiation therapy (rRT) in patients with an initial relapse of GBM. The subjects will be randomized into the treatment group (CAN008 + rRT) or the control group (rRT). The investigational treatment can be continued as long as the subjects have experienced lasting clinical benefits (complete response [CR], partial response [PR] or stable disease [SD]).

This study will be carried out in GBM subjects with an initial or second relapse. The subjects must have received standard care, including combination of radiotherapy and TMZ after surgical resection, and must be candidates for re-radiation therapy (rRT). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03746288
Study type Interventional
Source CANbridge Life Sciences Ltd.
Contact Wenbin Li
Phone 86-010-67096611
Email neure55@126.com
Status Not yet recruiting
Phase Phase 2
Start date November 20, 2018
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06147505 - Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) Phase 1/Phase 2
Recruiting NCT05076513 - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Early Phase 1
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Terminated NCT03149575 - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Phase 3
Completed NCT01478178 - Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Phase 1/Phase 2
Terminated NCT03119064 - BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Recruiting NCT03758014 - Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients Phase 2/Phase 3
Terminated NCT01205334 - Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme Phase 1/Phase 2
Active, not recruiting NCT00114309 - 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Phase 2
Terminated NCT04681677 - Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab Phase 2
Completed NCT01856933 - BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Phase 2
Terminated NCT04763031 - Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT N/A
Completed NCT00107003 - GW572016 to Treat Recurrent Malignant Brain Tumors Phase 2
Completed NCT03426891 - Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT06092255 - A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM. N/A
Recruiting NCT04115761 - Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients Phase 2
Recruiting NCT05954858 - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma N/A
Not yet recruiting NCT06388733 - A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Phase 3
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2